Risk of meningioma in European patients treated with growth hormone in childhood: results from the SAGhE cohort.

Swerdlow, Anthony J; Cooke, Rosie; Beckers, Dominique; Butler, Gary; Carel, Jean-Claude; Cianfarani, Stefano; Clayton, Peter; Coste, Joël; Deodati, Annalisa; Ecosse, Emmanuel; Hokken-Koelega, Anita C S; Khan, Aysha J; Kiess, Wieland; Kuehni, Claudia E; Flück Pandey, Christa Emma; Pfaffle, Roland; Sävendahl, Lars; Sommer, Grit; Thomas, Muriel; Tidblad, Anders; ... (2019). Risk of meningioma in European patients treated with growth hormone in childhood: results from the SAGhE cohort. Journal of clinical endocrinology and metabolism, 104(3), pp. 658-664. Endocrine Society 10.1210/jc.2018-01133

Preview

Text Swerdlow JClinEndocrinolMetab 2018.pdf - Accepted Version Available under License Publisher holds Copyright. Download (286kB) | Preview

Context

There has been concern that growth hormone (GH) treatment of children might increase meningioma risk. Results of published studies have been inconsistent and limited.

Objective

To examine meningioma risks in relation to GH treatment.

Design

Cohort study with follow-up via cancer registries and other registers.

Setting

Population-based.

Patients

A cohort of 10,403 patients treated in childhood with recombinant GH (r-hGH) in 5 European countries since this treatment was first used in 1984. Expected rates from national cancer registration statistics.

Main Outcome Measures

Risk of meningioma incidence.

Results

During follow-up 38 meningiomas occurred. Meningioma risk was greatly raised in the cohort overall (SIR=75.4; 95% confidence interval (CI) 54.9-103.6), as a consequence of high risk in subjects who had received radiotherapy for underlying malignancy (SIR= 658.4; 95% CI 460.4-941.7). Risk was not significantly raised in patients who did not receive radiotherapy. Risk in radiotherapy-treated patients was not significantly related to mean daily dose of GH, duration of GH treatment or cumulative dose of GH.

Conclusions

Our data add to evidence of very high risk of meningioma in patients treated in childhood with GH after cranial radiotherapy, but suggest that GH may not affect radiotherapy-related risk, and that there is no material raised risk of meningioma in GH-treated patients who did not receive radiotherapy.

Interest & Impact

Downloads

148 since deposited on 12 Sep 2018
32 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item